title: Zidovudine kinetics in the pregnant baboon.
abstract: The devastating impact of human immunodeficiency virus (HIV) infection during pregnancy has made the pharmacologic evaluation of potentially therapeutic agents of high priority. The results presented here are the maternal pharmacokinetics from a series of experiments to delineate more clearly the complex maternal-fetal pharmacokinetics and the effects of AZT in the chronically instrumented maternal and fetal baboon during both steady state intravenous infusion and oral bolus dosage regimens. Two results of major clinical importance were found. First, during pregnancy, both the clearance and volume of distribution of AZT were increased. Plasma clearance in the pregnant animals was 51 +/- 10 ml/min/kg compared with 37 +/- 2 ml/min/kg in the nonpregnant animals, and steady state volume of distribution was 3.7 +/- 1.21/kg compared with 2.2 +/- 0.61/kg. Second, with continuous intravenous infusion plasma drug concentrations were easily maintained in the therapeutic range, whereas with oral administration plasma concentration fell below therapeutic levels within 2 h of the dose being given. Because maternal plasma concentrations are a major determinant of drug concentration achieved in the fetus, an understanding of drug kinetics in pregnancy is of vital importance when making recommendations regarding optimal drug therapy during pregnancy to maximize the beneficial effect--the prevention of HIV infection in children.
authors.affiliation: College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
authors.forename: M
authors.initials: M
authors.lastname: Garland
authors.forename: H H
authors.initials: HH
authors.lastname: Szeto
authors.forename: S S
authors.initials: SS
authors.lastname: Daniel
authors.forename: P J
authors.initials: PJ
authors.lastname: Tropper
authors.forename: M M
authors.initials: MM
authors.lastname: Myers
authors.forename: R I
authors.initials: RI
authors.lastname: Stark
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D005260:Female; D005312:Fetal Blood; D005865:Gestational Age; D006207:Half-Life; D007262:Infusions, Intravenous; D008431:Maternal-Fetal Exchange; D010215:Papio; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000378:metabolism*; D014018:Tissue Distribution; D015215:Zidovudine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*
chemical_list: D000998:Antiviral Agents; D015215:Zidovudine; C055886:3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine